MedTrace Logo

GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir

NCT00883935 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2009-06-22

No results posted yet for this study

Summary

The purpose of this study is to compare the amount of GSK1349572 (study drug) in the blood when given with and without atazanavir/ritonavir or atazanavir and to compare the blood levels of atazanavir when given with GSK1349572 to historical data for atazanavir.

Conditions

  • Healthy Volunteer

Interventions

DRUG

GSK1349572

GSK1349572 30 mg once a day for 5 days in Period 1 and 14 days in Period 2

DRUG

Atazanavir 300 mg

Atazanavir 300 mg once per day for 14 days in Period 2

DRUG

Atazanavir 400 mg

Atazanavir 400 mg once a day for 14 days in Period 2

DRUG

Ritonavir

Ritonavir 100 mg once a day for 14 days in Period 2

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00883935 on ClinicalTrials.gov